Early versus deferred anti-SARS-CoV-2 convalescent plasma in patients admitted for COVID-19: A randomized phase II clinical trial.

Saved in:
Bibliographic Details
Title: Early versus deferred anti-SARS-CoV-2 convalescent plasma in patients admitted for COVID-19: A randomized phase II clinical trial.
Authors: Balcells ME; Department of Infectious Diseases, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile., Rojas L; Department of Internal Medicine, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile.; Program of Pharmacology and Toxicology, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile., Le Corre N; Department of Pediatric Infectious Diseases and Immunology, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile.; Diagnostic Virology Laboratory, Red de Salud UC CHRISTUS, Santiago, Chile., Martínez-Valdebenito C; Department of Pediatric Infectious Diseases and Immunology, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile.; Diagnostic Virology Laboratory, Red de Salud UC CHRISTUS, Santiago, Chile., Ceballos ME; Department of Infectious Diseases, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile., Ferrés M; Department of Pediatric Infectious Diseases and Immunology, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile.; Diagnostic Virology Laboratory, Red de Salud UC CHRISTUS, Santiago, Chile., Chang M; Department of Hematology and Oncology, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile., Vizcaya C; Department of Pediatric Infectious Diseases and Immunology, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile., Mondaca S; Department of Hematology and Oncology, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile., Huete Á; Department of Radiology, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile., Castro R; Department of Intensive Care Medicine, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile., Sarmiento M; Department of Hematology and Oncology, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile., Villarroel L; Department of Public Health, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile., Pizarro A; Department of Infectious Diseases, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile., Ross P; Department of Internal Medicine, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile., Santander J; Department of Psychiatry, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile., Lara B; Emergency Medicine Section, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile., Ferrada M; Clinical Research Center, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile., Vargas-Salas S; Department of Hematology and Oncology, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile., Beltrán-Pavez C; Laboratory of Molecular and Cellular Virology, Virology Program, Institute of Biomedical Sciences, Faculty of Medicine, Universidad de Chile, Santiago, Chile.; HIV/AIDS Work Group, Faculty of Medicine, Universidad de Chile, Santiago, Chile., Soto-Rifo R; Laboratory of Molecular and Cellular Virology, Virology Program, Institute of Biomedical Sciences, Faculty of Medicine, Universidad de Chile, Santiago, Chile.; HIV/AIDS Work Group, Faculty of Medicine, Universidad de Chile, Santiago, Chile., Valiente-Echeverría F; Laboratory of Molecular and Cellular Virology, Virology Program, Institute of Biomedical Sciences, Faculty of Medicine, Universidad de Chile, Santiago, Chile.; HIV/AIDS Work Group, Faculty of Medicine, Universidad de Chile, Santiago, Chile., Caglevic C; Instituto Oncológico Fundación Arturo López Pérez, Santiago, Chile., Mahave M; Instituto Oncológico Fundación Arturo López Pérez, Santiago, Chile., Selman C; Instituto Oncológico Fundación Arturo López Pérez, Santiago, Chile., Gazitúa R; Instituto Oncológico Fundación Arturo López Pérez, Santiago, Chile., Briones JL; Instituto Oncológico Fundación Arturo López Pérez, Santiago, Chile., Villarroel-Espindola F; Instituto Oncológico Fundación Arturo López Pérez, Santiago, Chile.; Translational Medicine Research Laboratory, Fundación Arturo López Pérez, Santiago, Chile., Balmaceda C; Health Technology Assessment Unit, Clinical Research Center, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile., Espinoza MA; Department of Public Health, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile., Pereira J; Department of Hematology and Oncology, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile., Nervi B; Department of Hematology and Oncology, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile.
Source: PLoS medicine [PLoS Med] 2021 Mar 03; Vol. 18 (3), pp. e1003415. Date of Electronic Publication: 2021 Mar 03 (Print Publication: 2021).
Publication Type: Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Public Library of Science Country of Publication: United States NLM ID: 101231360 Publication Model: eCollection Cited Medium: Internet ISSN: 1549-1676 (Electronic) Linking ISSN: 15491277 NLM ISO Abbreviation: PLoS Med Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1549-1676
DOI:10.1371/journal.pmed.1003415